JP2008508903A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508903A5
JP2008508903A5 JP2007526144A JP2007526144A JP2008508903A5 JP 2008508903 A5 JP2008508903 A5 JP 2008508903A5 JP 2007526144 A JP2007526144 A JP 2007526144A JP 2007526144 A JP2007526144 A JP 2007526144A JP 2008508903 A5 JP2008508903 A5 JP 2008508903A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
protein
complementarity determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007526144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508903A (ja
JP5026268B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2005/000899 external-priority patent/WO2005121341A1/en
Publication of JP2008508903A publication Critical patent/JP2008508903A/ja
Publication of JP2008508903A5 publication Critical patent/JP2008508903A5/ja
Application granted granted Critical
Publication of JP5026268B2 publication Critical patent/JP5026268B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007526144A 2004-06-10 2005-06-10 腫瘍特異的抗体 Expired - Fee Related JP5026268B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57829104P 2004-06-10 2004-06-10
US60/578,291 2004-06-10
PCT/CA2005/000899 WO2005121341A1 (en) 2004-06-10 2005-06-10 Tumor specific antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012078467A Division JP2012187104A (ja) 2004-06-10 2012-03-30 腫瘍特異的抗体

Publications (3)

Publication Number Publication Date
JP2008508903A JP2008508903A (ja) 2008-03-27
JP2008508903A5 true JP2008508903A5 (enExample) 2008-07-24
JP5026268B2 JP5026268B2 (ja) 2012-09-12

Family

ID=35503067

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007526144A Expired - Fee Related JP5026268B2 (ja) 2004-06-10 2005-06-10 腫瘍特異的抗体
JP2012078467A Pending JP2012187104A (ja) 2004-06-10 2012-03-30 腫瘍特異的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012078467A Pending JP2012187104A (ja) 2004-06-10 2012-03-30 腫瘍特異的抗体

Country Status (11)

Country Link
US (3) US8383117B2 (enExample)
EP (2) EP1766017B1 (enExample)
JP (2) JP5026268B2 (enExample)
CN (1) CN101044242B (enExample)
AU (1) AU2005252275B2 (enExample)
CA (1) CA2569788C (enExample)
ES (1) ES2535229T3 (enExample)
IL (1) IL179891A (enExample)
NZ (1) NZ552476A (enExample)
PL (1) PL1766017T3 (enExample)
WO (1) WO2005121341A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2829283T3 (en) 2003-04-30 2017-09-18 Univ Zuerich METHOD OF TREATING CANCER USING IMMUNOTOXIN
PL1737961T3 (pl) 2004-03-19 2013-12-31 Merck Patent Gmbh Zmodyfikowane białka bouganiny, cytotoksyny i sposoby oraz ich zastosowania
WO2007071061A1 (en) * 2005-12-23 2007-06-28 Viventia Biotech Inc. Methods for generating and screening fusion protein libraries and uses thereof
WO2008128330A1 (en) * 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
GB0718045D0 (en) 2007-09-14 2007-10-24 Peptcell Ltd Pharmaceutical compound
CA2700815A1 (en) 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
EP2231184A4 (en) * 2007-12-21 2012-02-15 Univ Rochester CD24 AS A STEM CELL MARKER FOR BRAIN TUMOR AND DIAGNOSTIC AND THERAPEUTIC TARGET MOLECULAR IN PRIMARY NEURONAL AND GLIAL BRAIN TUMORS
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
US20100008978A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
TWI404931B (zh) * 2009-02-20 2013-08-11 財團法人國家同步輻射研究中心 癌化生物樣本之檢測方法及其使用之檢驗試劑
JP6041333B2 (ja) * 2011-01-13 2016-12-07 学校法人近畿大学 抗腫瘍剤
DK3387898T3 (da) * 2013-03-15 2020-08-03 Mayo Found Medical Education & Res Identificering og monitorering af monoklonale immunglobuliner ved hjælp af molekylvægt
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
BR112016007232A2 (en) 2013-10-02 2018-01-23 Viventia Bio Inc. anti-epcam antibodies and methods of use
CA2944767C (en) 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
WO2016018978A1 (en) 2014-07-29 2016-02-04 Mayo Foundation For Medical Education And Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
WO2016068294A1 (ja) * 2014-10-31 2016-05-06 株式会社カネカ タンパク質合成阻害タンパク質毒素を含むポリペプチドの製造方法
JP6847846B2 (ja) 2015-03-12 2021-03-24 セセン バイオ,インコーポレイテッド Epcam陽性膀胱癌を標的とする投薬戦略
AU2016228755B2 (en) 2015-03-12 2020-09-10 Viventia Bio Inc. Methods of treatment for EPCAM positive bladder cancer
WO2016187571A2 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Her2 immunotoxins and methods of using the same
AU2016306527B2 (en) * 2015-08-12 2022-03-17 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same
EP3353200A4 (en) 2015-09-24 2019-06-26 Mayo Foundation for Medical Education and Research IDENTIFICATION OF FREE LIGHT CHAINS FROM IMMOBILIZED LOBULIN BY MASS SPECTROMETRY
CN105510586B (zh) * 2015-12-22 2017-09-12 湖北鹊景生物医学有限公司 用于肺癌诊断的试剂盒及其使用方法
EP3523647B1 (en) 2016-09-07 2024-06-26 Mayo Foundation for Medical Education and Research Identification and monitoring of cleaved immunoglobulins by molecular mass
EP3681907A4 (en) 2017-09-13 2021-07-07 Mayo Foundation for Medical Education and Research IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN J-CHAINS
EP3681528B1 (en) 2017-09-13 2025-07-23 Mayo Foundation for Medical Education and Research Identification and monitoring of apoptosis inhibitor of macrophage
CN109324189B (zh) * 2018-08-15 2021-10-01 泰达国际心血管病医院 多蛋白组合物的应用及先天性心脏病筛查试剂盒
CN111138521B (zh) * 2018-11-06 2022-10-28 香雪生命科学技术(广东)有限公司 源自于afp抗原的短肽
PT3806895T (pt) * 2019-02-15 2023-07-27 Atreca Inc Anticorpos que se ligam a tecido tumoral para diagnóstico e terapia
CN112300261B (zh) * 2019-07-23 2023-03-17 香雪生命科学技术(广东)有限公司 一种衍生自afp的肿瘤抗原短肽
CN112851811B (zh) * 2021-01-28 2022-08-09 姜国胜 一种cd44v6纳米抗体及其作为白血病研究试剂的应用
CN114773478B (zh) * 2022-03-14 2023-05-23 深圳市国创纳米抗体技术有限公司 抗afp抗原vhh结构域及含有其的双特异性抗体
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116297727B (zh) * 2022-09-13 2024-01-23 山东大学齐鲁医院 一种甲胎蛋白和异常凝血酶原电致发光传感器的制备及其应用
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
CN1042940A (zh) * 1988-12-01 1990-06-13 中国农业科学院哈尔滨兽医研究所 马传贫病马与接种弱毒疫苗马的血清抗体鉴别诊断试剂
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
US5863540A (en) * 1991-03-15 1999-01-26 Duke University Adhesion molecule
CN1075208A (zh) * 1992-12-02 1993-08-11 张昌卿 一种检测eb病毒抗体的显色试剂及其制造方法
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
JP2003299497A (ja) * 2002-02-05 2003-10-21 Masayoshi Kachi ムコ多糖類及びその製造方法
AU2003209059A1 (en) * 2002-02-08 2003-09-02 Genetastix Corporation Human monoclonal antibodies against membrane proteins
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
PL1737961T3 (pl) 2004-03-19 2013-12-31 Merck Patent Gmbh Zmodyfikowane białka bouganiny, cytotoksyny i sposoby oraz ich zastosowania
US8802442B2 (en) 2011-11-30 2014-08-12 Eric B. Wheeldon Apparatus and method for the remote sensing of blood in human feces and urine

Similar Documents

Publication Publication Date Title
US10494435B2 (en) Human monoclonal antibodies specific for CD22
CN105026429B (zh) 间皮素结构域-特异性单克隆抗体及其用途
JP2011501946A5 (enExample)
US12037404B2 (en) Human monoclonal antibodies against EphA4 and their use
CN112533633A (zh) Cd4的抗原结合构建体
TW202146456A (zh) 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
JP2005518789A5 (enExample)
JP2010537671A5 (enExample)
JP2012525432A5 (enExample)
JP2011525354A5 (enExample)
JP6612324B2 (ja) αKlothoに対して高親和性を有する抗体
JP2023508174A5 (enExample)
JP2017509594A (ja) マトリプターゼ及びu‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
JP2019506140A5 (enExample)
JP7743406B2 (ja) 抗bcma car抗体、コンジュゲートおよび使用方法
JP2023508173A5 (enExample)
JP2023502990A5 (enExample)
CN119013305A (zh) 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物
CN116249547A (zh) 脑特异性血管生成抑制剂1(bai1)抗体及其用途
CN119343378A (zh) 靶向itga2的抗体和包含此抗体的抗体药物缀合物
CN101432308A (zh) Fas结合抗体
JP2008523825A5 (enExample)
JP2020533955A5 (enExample)
US11377504B2 (en) Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same
WO2017055511A1 (en) Compositions and methods for inhibiting cancer stem cells